Understanding Non-Alcoholic Steatohepatitis (NASH): Causes, Diagnosis & Treatment
Non-Alcoholic Steatohepatitis, or NASH, is a type of Non-Alcoholic Fatty Liver Disease (NAFLD). Unlike alcohol related liver damage, NASH is caused by too much fat accumulating in the liver which causes inflammation and harm to liver cells [1]. Over time this can lead to scarring (fibrosis), cirrhosis or even liver cancer – specifically hepatocellular carcinoma (HCC).
Table of Contents
In NASH, fat builds up in liver cells and they balloon. The causes of fat in the liver are not fully understood and while certain health conditions may contribute to NAFLD, some people develop NAFLD with no known risk factors. When this balloon-ization persists it damages the liver's ability to filter out bad stuff and support digestion. Because NASH develops silently people may not notice anything at first. Some may just feel tired or a mild ache on the right side of the upper abdomen. Others may find out they have NASH after a routine blood test shows elevated liver enzymes and they get checked out [1], [2]. This particular form of liver disease is different from others such as Hepatitis B, C, D, E, and NAFLD.
NASH is a complex condition with multiple contributing factors. Obesity is a major risk factor, as excess body weight can lead to fat accumulation in the liver, setting the stage for NASH. Insulin resistance, often preceding type 2 diabetes, is another significant factor, as it can promote fat storage in the liver.
Metabolic syndrome, which includes high blood pressure, high cholesterol, and insulin resistance, increases NASH risk. Women with polycystic ovary syndrome (PCOS) face a higher risk due to hormonal imbalances and insulin resistance. A family history of liver disease or NASH also raises the likelihood of developing the condition.
Other key risk factors include high blood pressure and high LDL cholesterol, both of which can contribute to liver damage and NASH progression. Understanding these risk factors is crucial for early detection and prevention of this serious liver disease.
Doctors diagnose NASH by confirming fat in the liver, ruling out high alcohol use and other liver diseases (like viral hepatitis). Recently the term 'metabolic dysfunction associated steatohepatitis' (MASH) has been introduced to better reflect the underlying metabolic issues. Key tests include:*
Treating Non-Alcoholic Steatohepatitis (NASH) involves a combination of lifestyle changes and medical interventions aimed at reducing liver fat, inflammation and scarring. Key strategies include:
Overall, managing NASH involves a comprehensive approach that includes adopting a healthy lifestyle, monitoring by healthcare professionals and considering medications when appropriate. This multi-faceted strategy is essential to prevent complications such as liver cancer, cardiovascular diseases and the need for a liver transplant.
NASH can lead to severe complications such as liver cancer and the need for a liver transplant. Chronic liver damage increases the risk of liver cells becoming cancerous. In cases of extensive liver damage a transplant may be required to replace the failing liver. NASH also increases the risk of cardiovascular disease (heart attacks and strokes) due to its association with metabolic syndrome. Type 2 diabetes and kidney disease are also potential complications as insulin resistance and advanced liver damage affects kidney function. Managing NASH is key to preventing these serious health issues.
Since NASH can progress silently doctors often schedule regular checkups and scans every 6-24 months. These may include:
Scarring in the liver (fibrosis) can progress to cirrhosis and limit liver functions. People with cirrhosis can experience fluid retention, confusion due to toxin buildup and increased risk of HCC [1]. Those with NAFLD are at higher risk of heart disease which is the leading cause of death in this condition [4]. Managing NASH often means managing overall health including blood pressure, cholesterol and blood sugar.
NASH is a serious liver disease with fat accumulation, inflammation and potential scarring. Early detection can be difficult as the condition can progress without symptoms. However blood tests and imaging scans can help doctors identify problems before they get worse. The best defense is a balanced diet, regular exercise and moderate weight loss. Meds can support that in certain situations and ongoing studies are exploring new treatments [3]. With regular monitoring and healthier habits many can protect their liver and reduce risk of complications.
[1] Tokushige, K., Ikejima, K., Ono, M., Eguchi, Y., Kamada, Y., Itoh, Y., Akuta, N., Yoneda, M., Iwasa, M., Yoneda, M., Otsuka, M., Tamaki, N., Kogiso, T., Miwa, H., Chayama, K., Enomoto, N., Shimosegawa, T., Takehara, T., & Koike, K. (2021). Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatology research : the official journal of the Japan Society of Hepatology, 51(10), 1013–1025. https://doi.org/10.1111/hepr.13688
[2] Long, M. T., Noureddin, M., & Lim, J. K. (2022). AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology, 163(3), 764–774.e1. https://doi.org/10.1053/j.gastro.2022.06.023
[3] Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., Taub, R., & Moussa, S. E. (2019). Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 394(10213), 2012–2024. https://doi.org/10.1016/S0140-6736(19)32517-6
[4] Tokushige, K., Ikejima, K., Ono, M., Eguchi, Y., Kamada, Y., Itoh, Y., Akuta, N., Yoneda, M., Iwasa, M., Yoneda, M., Otsuka, M., Tamaki, N., Kogiso, T., Miwa, H., Chayama, K., Enomoto, N., Shimosegawa, T., Takehara, T., & Koike, K. (2021). Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Journal of gastroenterology, 56(11), 951–963. https://doi.org/10.1007/s00535-021-01796-x
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
17 hours ago
- News24
Missed, misunderstood, and deadly: A Cape Town family's heartbreak with hepatitis B
When Desmond Pedro discovered a strange hardness under his ribcage, he was just 30 and preparing for a fresh start on a government skills course. Little did he know that he would soon die of liver cancer caused by undetected hepatitis B. Spotlight spent time with his family and spoke to experts to uncover how this overlooked virus continues to claim lives. Desmond Pedro was getting ready to attend a course at a college in Bellville in Cape Town when he noticed a hardness under his ribcage. The 30-year-old unemployed father of two small children hoped to learn skills on the government-sponsored boiler-making course. The strange condition worried him. When Desmond first went to a clinic, nurses said it wasn't serious and gave him laxatives for constipation. He returned three times and got the same response. On his fourth visit, Desmond's wife went with him, and she insisted on a scan. Two weeks later, while on his way to college, he returned to receive the results. His older brother, Mario tells the story: 'When he arrived, the clinic staff wouldn't let him leave. An ambulance took him to Tygerberg Hospital. We visited him that night but were told nothing. We felt helpless.' About a week later, Desmond asked Mario to meet him at Tygerberg's oncology unit, where a doctor delivered the news of his diagnosis. 'When I arrived, he was in agony and couldn't stand up straight. This had all happened within two to three weeks. A porter brought a wheelchair, and we went into the doctor's office where the doctor told us hepatitis B had brought on Desmond's liver cancer.' Hepatitis means that the liver is swollen or irritated. This can happen for many reasons, such as infections from viruses or bacteria, parasites, injuries, or when the body's immune system mistakenly attacks the liver. Viral hepatitis is a type of liver inflammation caused by a virus. There are five main types: A, B, C, D and E. As Spotlight previously reported, new, highly effective cures for hepatitis C are slowly becoming more widely available in South Africa. Where did it come from? Until Desmond's cancer diagnosis, he had no idea that he was carrying the hepatitis B virus in his body, nor where he contracted it. The virus is transmitted from person to person through blood, semen or other body fluids. It can, for instance, be passed from pregnant women infected with the hepatitis B virus to their babies during childbirth, through sexual contact with an infected person, sharing of needles carrying traces of infected blood, and accidental needlestick injuries in health workers working with people who have the virus. After Desmond's diagnosis, his entire family were tested. Mario said: Both myself and my youngest brother, Johan tested positive for hepatitis B. To this day, we don't know where we got it or if we ever had the vaccine. 'At the time, I was 33. My mother was negative, as were our wives and all the children. For Desmond, it was too late.' Once infected, some people have strong enough immune systems to fight off the infection and usually clear it within six months. This is called acute or short-term infection. People who get infected as adults normally have acute infections. In long-term or chronic cases, it lasts more than six months and can lead to liver failure, liver cancer or cirrhosis - a condition where scar tissue has replaced healthy tissue to such an extent that the liver can no longer function. The younger a person is when they contract the virus, the higher their risk of the condition becoming chronic, particularly in the case of newborn babies or children under five. In most cases, people with chronic infection show no symptoms for years until they become seriously ill from liver disease. A silent killer One of the reasons that viral hepatitis can go undetected, as it did for Desmond, is that it is often asymptomatic. Symptoms, for those who do get them, can start as soon as two weeks after infection and include stomach pain, joint pain, fever, extreme fatigue, dark urine and jaundice - a yellowing of the skin and whites of the eyes. Professor Mark Sonderup, Associate Professor in the Department of Medicine and Division of Hepatology at the University of Cape Town, explains that with chronic inflammation in the liver, the body's attempt to heal the inflammation drives scarring, or fibrosis, of the liver. Over 10, 20 or 30 years, he says, there's a serious risk of cirrhosis. ALSO READ | Stem cell transplant recovery hinges on living conditions - transplant donor organisation 'The other risk of hepatitis B, which increases dramatically as the scarring worsens, is that because the virus is a DNA virus and inserts itself into the DNA of the liver cell, it dramatically increases the risk of liver cancer which is why hepatitis B accounts for most liver cancer in the world.' Sonderup says hepatitis B is endemic in South Africa and the region. He cites figures pegging the country's chronic infection rate at just below 5%, which suggests there are in the region of three million people living with the infection in South Africa. Most cases can be treated Chronic infection can usually be treated successfully with antiviral medicines if diagnosed in time. These medicines have to be taken for life since they suppress, but do not eliminate the virus. For acute infection there are much fewer treatment options. Those with serious liver damage often need a liver transplant. Since their diagnosis, Mario and Johan have been going to the Groote Schuur Liver Clinic where he says they are in good hands. 'They've been there for us from the start,' says Mario. The brothers are both on tenofovir, an anti-retroviral used to treat chronic hepatitis B infection. READ MORE | Why most people in South Africa can't get the shingles vaccine 'We take one tiny tablet a day, which suppresses our viral load and has no side effects. I take my tablet religiously at the same time every night.' Tenofovir is also part of standard HIV treatment in South Africa. As such, it is taken by more than five million people in the country, some of whom will happen to have undiagnosed hepatitis B infection. Sadly, Desmond's diagnosis came too late for antiviral treatment to save him. Mario recalls: I'll never forget the look on Desmond's face when the doctor said there was nothing they could do. 'The liver cancer was aggressive. He died at home about four weeks later. The time between getting his results and passing away was about two months.' It is for this reason that Mario has become such a passionate advocate for hepatitis B testing. 'All it takes is a simple blood test, and if it's caught in time, you take one small tablet daily. There are no side effects and you're good to go,' he says. Mario reckons nurses testing for HIV should be testing for hepatitis B at the same time. A highly effective vaccine One piece of good news is that many people in South Africa, especially those younger than 30 years of age, would have been vaccinated against the hepatitis B virus as babies. The South African government began rolling out the vaccine in 1995, starting with a three-dose schedule for babies, administered at 6, 10, and 14 weeks. 'It took a while to reach full coverage across the entire country. To date, our numbers lag a little behind, in that full three dose coverage is somewhere in the mid 80 percent in South Africa,' says Sonderup. 'This is pretty decent, except that we do have babies born to women who are inadvertently chronically infected, and there's a full six-week period before the first dose of vaccine is given.' READ MORE | The US funded 40% of SA's data capturers: Why losing them is so dangerous In other words, there's a six-week gap before babies receive their first hepatitis B vaccine, leaving them unprotected during that time. This is why Sonderup recommends giving a vaccine birth dose within the first 24 hours after birth alongside the standard polio and BCG vaccines all newborns receive. 'This would be followed by the second, third and fourth doses at 6,10 and 14 weeks. This has been shown to completely shut down that potential six-week period where a baby may be exposed,' he says. A phased approach Dr Kgomotso Vilakazi-Nhlapo, the top hepatitis official in the National Department of Health, agrees that a birth dose is important. However, she says that due to resource challenges, the department has opted for a phased approach. 'Instead of starting with the implementation of the universal hepatitis B birth dose vaccination, we test all pregnant women for the hepatitis B virus, treat those who are hepatitis B positive (and HIV negative) and offer the hepatitis B birth dose vaccine to newborn babies of pregnant women who tested positive for hepatitis B,' she says. According to Vilakazi-Nhlapo, this approach was implemented in April 2023 in all public health facilities but by the end of December 2024, they were only testing about 50% of pregnant women. READ MORE | Common weed shows potential to fight cancer, UJ researchers find 'This meant that women among the 50 percent who were not tested could be positive for hepatitis B and be transmitting the infection to their babies,' she says. 'Of course, it would be preferable to give a universal birth dose to all newborns, but, unfortunately, the budget and human resources remains an issue.' Vilakazi-Nhlapo estimates that with around a million births per year and hepatitis B prevalence of around 5%, every year in the region of 50 000 women living with the virus are giving birth in South Africa. What to do Sonderup says the solutions to South Africa's hepatitis B problem are neither complex nor overly expensive. 'Firstly,' he says, 'we need to fully implement the universal birth dose vaccination; secondly, we need to ensure children complete their vaccine schedule in total, thirdly we need to screen pregnant woman and link them to additional care.' He also says that in a country where almost 5% of people are living with the virus, everyone should be screened for hepatitis B at least once as we do with regular HIV testing. 'This can be done through a simple finger prick test and it's not expensive. People should at least know their status,' Sonderup says. South Africa's key hepatitis B policy document is the viral hepatitis treatment guidelines published in 2019. Sonderup, who was involved in the development of the guidelines, is concerned about its implementation. He blames 'policy inertia' and competition for limited resources for the country not having made greater progress against hepatitis B. 'But we can actually do a great deal with not very much, with significant impact, to eliminate a virus that continues to cause significant havoc,' he says. 'A shortage of resources, staff, and skills' For her part, Vilakazi-Nhlapo blames a lack of 'resources, staff, and skills' for there not being more progress. She says there is only one other person working with her on hepatitis at the national level, and no dedicated staff at provincial health departments. 'We work mainly with NGOs and civil society. Provincial physicians have helped us greatly to do our work but it's not enough,' Vilakazi-Nhlapo says. 'There is still insufficient knowledge both among healthcare workers and within communities about hepatitis B. For now, patients with hepatitis B are referred to hospitals … but the reality is that, if primary healthcare staff are managing HIV patients, they can manage hepatitis B patients,' she says. She adds that they are trying to integrate hepatitis into other health programmes, such as those for maternal and child health. 'Everyone should know their status' Back in Cape Town, Mario, now 45, says he feels healthy apart from the normal aches and pains associated with his age. He has become an advocate for more awareness about hepatitis B. 'We'd never have known we had it if this hadn't happened to my brother. It's a silent killer. Someone could be dying of it right now without knowing. Everyone should know their status,' he says.
Yahoo
a day ago
- Yahoo
EMA says Ozempic, Wegovy may cause rare eye condition
-- The European Medicines Agency's (EMA) safety committee, PRAC, said Friday that it has concluded that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare eye condition that can lead to vision loss, is a "very rare side effect" of semaglutide medicines, including Ozempic, Rybelsus, and Wegovy. The medications, owned by Novo Nordisk (NYSE:NVO), are widely used for the treatment of diabetes and obesity. Following a comprehensive review of all available data, including non-clinical studies, clinical trials, post-marketing surveillance, and medical literature, PRAC determined that NAION "may affect up to 1 in 10,000 people taking semaglutide." The firm explained that several large epidemiological studies indicate that adults with type 2 diabetes taking semaglutide face "an approximately two-fold increase in the risk of developing NAION" compared to those not on the medication. This is said to translate to about "one additional case of NAION per 10,000 person-years of treatment." The EMA added that clinical trial data also pointed to a "slightly higher risk" for those on semaglutide versus placebo. As a result, the EMA said it has recommended updating the product information for semaglutide medicines to include NAION as a "very rare" side effect. They conclude that patients experiencing "a sudden loss of vision or rapidly worsening eyesight" while on semaglutide are advised to contact their doctor immediately. If NAION is confirmed, "treatment with semaglutide should be stopped,' states the EMA. Related articles EMA says Ozempic, Wegovy may cause rare eye condition Virgin Galactic stock jumps on SpaceX competition speculation Vera Therapeutics stock sinks following competitor's successful trial
Yahoo
a day ago
- Yahoo
Cancer Risk at Air Force Missiles Sites Low 'But Not Zero,' Latest Service Data Shows
Airmen who watched over America's nuclear intercontinental ballistic missiles in Cold War-era facilities faced marginally higher risk of cancer due to contaminants found there and more workplace oversight is needed, according to the latest findings of an Air Force health study. Air Force Global Strike Command, during a town hall event Wednesday, released the latest data showing the slightly elevated cancer risk as part of its ongoing probe into health concerns for America's missileers, maintainers and other support roles at several bases in the Midwest and Western U.S. The lifetime cancer risk for all Americans is around 39%, and the Air Force's Health Risk Assessment found rates of 39.9% to 40.13% for men and women if they would have served anywhere from eight to 70 years in those jobs. Service officials said consistent workplace inspections and monitoring would likely be necessary to address the risks, which are caused by the presence of chemicals and toxins. Read Next: Army Faces Backlash over Plan to Divert Barracks Funds to Border Mission Contaminants linked to cancer were found during a series of environmental studies at F.E. Warren Air Force Base in Wyoming, Malmstrom Air Force Base in Montana, and Minot Air Force Base in North Dakota. "In summary, this health risk assessment characterizes the health risk as low but not zero," Col. Ric Speakman, the commander of the U.S. Air Force School of Aerospace Medicine, said during the town hall presentation. "Therefore, the appropriate action is to include missile alert facility workers in an occupational surveillance." Air Force Global Strike Command is still in the process of an ongoing epidemiological study and is gathering more data from states as well as national cancer registries before more definitive cancer and health conclusions can be made. Last year, reported in an investigative series that past probes by the Air Force into cancer concerns roughly two decades ago went ignored, and past and current missileers and nuclear missile maintainers raised alarms about the environmental conditions, toxins and chemical dangers they faced while in uniform. They believe the conditions made them sick. In the wake of reporting, the service announced changes that included new workplace inspections and health record tracking, and the spouse of a missileer who died from non-Hodgkin lymphoma was able to secure Department of Veterans Affairs benefits related to his death. While polychlorinated biphenyls, or PCBs, were one of the known outlawed carcinogenes that the Air Force's remediation efforts focused on, research shown during Wednesday's town hall showed there were other toxins detected as well that were factored into the service's health risk assessment. "Although only PCBs were detected at levels above the Environmental Protection Agency's standards for cleanup and remediation, the environmental sampling was sensitive enough to detect chemicals such as benzene and chloroform at levels well below standards for remediation," a Thursday news release from Air Force Global Strike Command following the town hall said. The Torchlight Initiative, a grassroots organization that began shortly after a Space Force officer and former Air Force missileer raised concerns about non-Hodgkin lymphoma rates at Malmstrom, released its own independent study in April examining the rates of blood cancer reported in its online health registry. That study found that service members were diagnosed at younger ages compared to the wider population. Air Force Global Strike Command officials briefly mentioned that study at the town hall, stating that, "while this study is separate from the missile community cancer study, it does add to the work advocacy and the well-being of the missile community." Representatives from the Torchlight Initiative were on Capitol Hill in early April alongside other advocacy groups, and made a plea to lawmakers in hopes of expanding the PACT Act -- a 2022 law that mostly covered veterans sickened by toxic exposure in war zones -- to cover those who experienced health issues stateside as well. "The Torchlight Initiative is happy to hear that Global Strike and U.S. Air Force School of Aerospace Medicine are still working on their long-term study and research," the organization said in a statement to on Thursday. "However, our focus and energy remains with the families who are disproportionately affected by these cancers and illnesses." The remaining data in the ongoing health study is slated to be released in late 2025. Gen. Thomas Bussiere, the head of Air Force Global Strike Command, said during the town hall he would advocate for a registry, if the VA also supported such a move, based on the study's findings. "The level of interest and oversight with the Department of the Air Force and Congress has not waned, and I'm very thankful and happy with the interest and actions on the part of the VA," Bussiere said in a news release after the town hall. "They've been great partners, and I anticipate they will continue to be great partners." Related: Independent Study Raises Alarm About Non-Hodgkin Lymphoma at Malmstrom Air Force Base
